Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
14.01
-0.06 (-0.43%)
At close: Mar 27, 2026, 4:00 PM EDT
14.06
+0.05 (0.36%)
After-hours: Mar 27, 2026, 7:51 PM EDT

Corvus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-15.28-62.29-27.03-41.31-43.24
Depreciation & Amortization
0.110.090.150.370.46
Stock-Based Compensation
5.3332.152.694.23
Other Adjustments
-26.5335.434.399.815.07
Change in Receivables
0.04-0.050.56-0.08-0.51
Changes in Accounts Payable
-0.091.06-0.450.41-1.9
Changes in Accrued Expenses
2.76-0.25-3.580.47-0.52
Changes in Other Operating Activities
0.87-2.41-0.130.62-0.3
Operating Cash Flow
-32.8-25.42-23.94-27.02-36.72
Capital Expenditures
-0.17--0.03-0.27-0.01
Sale of Property, Plant & Equipment
-0.01-0.02-
Purchases of Investments
-91.75-70.12-47.05-66.19-9.36
Proceeds from Sale of Investments
84.1342.6362.6243.1630.92
Investing Cash Flow
-7.8-27.4815.54-23.2821.56
Issuance of Common Stock
36.4349.037.86-62.16
Net Common Stock Issued (Repurchased)
36.4349.037.86-62.16
Financing Cash Flow
36.4349.037.86-62.16
Net Cash Flow
-4.16-3.88-0.54-50.347
Free Cash Flow
-32.97-25.42-23.97-27.29-36.72
Free Cash Flow Per Share
-0.41-0.42-0.50-0.59-0.88
Levered Free Cash Flow
-11.81-63.81-31.07-39.72-45.52
Unlevered Free Cash Flow
-39.5-29.06-27.45-30.97-40.9
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q